DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: NNC0174-0833

First Posted Date: 2019-12-23

Last Posted Date: 2021-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT04209049

Locations: 🇺🇸
Novo Nordisk Investigational Site, Orlando, Florida, United States

A Research Study Investigating Mim8 in People With Haemophilia A

Phase 2

Completed

Conditions: Haemophilia A With or Without Inhibitors
Healthy Volunteers

Interventions: Drug: Placebo (Mim8)
Drug: NNC0365-3769 (Mim8)

First Posted Date: 2019-12-19

Last Posted Date: 2024-10-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 275

Registration Number: NCT04204408

Locations: 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
Rush University Med. Cntr, Chicago, Illinois, United States
🇺🇸
University of Iowa_Iowa City, Iowa City, Iowa, United States

and more 19 locations

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Phase 4

Completed

Conditions: Overweight
Healthy Volunteers
Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Semaglutide
Drug: Dulaglutide

First Posted Date: 2019-12-06

Last Posted Date: 2022-11-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT04189848

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Semaglutide

First Posted Date: 2019-12-05

Last Posted Date: 2021-11-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT04187300

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Phase 1

Completed

Conditions: Healthy Volunteers
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2019-11-05

Last Posted Date: 2021-11-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT04152915

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Phase 2

Completed

Conditions: Healthy Volunteers Overweight
Healthy Volunteers Diabetes Mellitus, Type 2
Healthy Volunteers Obesity

Interventions: Drug: Semaglutide (administered by DV3396 pen)
Drug: Semaglutide (administered by PDS290 pen)

First Posted Date: 2019-10-30

Last Posted Date: 2021-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT04143945

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0268-0965
Drug: insulin glargine

First Posted Date: 2019-10-23

Last Posted Date: 2022-09-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT04136067

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

Phase 1

Completed

Conditions: Healthy Volunteers
Type 2 Diabetes

Interventions: Drug: Oral semaglutide

First Posted Date: 2019-09-30

Last Posted Date: 2021-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 278

Registration Number: NCT04109508

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Oral semaglutide
Drug: Placebo

First Posted Date: 2019-09-30

Last Posted Date: 2023-09-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 521

Registration Number: NCT04109547

Locations: 🇩🇿
Bouzareah Diabetic House Algiers Algeria, Algiers, Algeria
🇩🇿
UH of Douera, Algiers, Algeria
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 63 locations

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Other: Placebo
Drug: Semaglutide

First Posted Date: 2019-09-25

Last Posted Date: 2024-01-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 201

Registration Number: NCT04102189

Locations: 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy